Question 1

What is the catalog number for Suc-Ala-Ala-Ala-Ala-Ala-pNA?

Accepted Answer

The catalog number for Suc-Ala-Ala-Ala-Ala-Ala-pNA is 242084.

Question 2

What sizes are available for Suc-Ala-Ala-Ala-Ala-Ala-pNA?

Accepted Answer

Suc-Ala-Ala-Ala-Ala-Ala-pNA is available in the following size(s): 5 mg, 25 mg, 100 mg.

Question 3

How many pack sizes does Suc-Ala-Ala-Ala-Ala-Ala-pNA come in?

Accepted Answer

Suc-Ala-Ala-Ala-Ala-Ala-pNA is available in 3 different pack sizes.

Question 4

Is Suc-Ala-Ala-Ala-Ala-Ala-pNA in stock?

Accepted Answer

Suc-Ala-Ala-Ala-Ala-Ala-pNA is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

What is the molecular weight of the target protein?

Accepted Answer

Molecular weight information, where applicable, is listed on the datasheet under target details, useful for confirming the correct band on western blot.

Question 6

How long will it take to receive this product if it’s custom made?

Accepted Answer

Lead times depend on the product type: custom polyclonal antibodies typically take 12-14 weeks, monoclonal antibodies 15-17 weeks, made-to-order recombinant proteins 4-8 weeks, and made-to-order recombinant antibodies 6-8 weeks. These are estimates and may shift due to production delays.

Question 7

What is the recommended dilution for this antibody?

Accepted Answer

A recommended dilution range for each validated application is provided on the datasheet, but optimal dilution should be titrated for your specific experimental system, sample type, and detection method.

Suc-Ala-Ala-Ala-Ala-Ala-pNA

Product Specifications

Available Sizes

Frequently Asked Questions

Explore Other Products

Ku-Holo (p70;83) (KU729), CF488A conjugate, 0.1mg/mL

TFIIB (GTF2B) Mouse Monoclonal Antibody [Clone ID: OTI5B6]

Fetuin A (AHSG) (NM_001622) Human Over-expression Lysate

Elab Fluor® Violet 540 Anti-Human CD11b Antibody[ICRF44]

Elab Fluor® Violet 540 Anti-Human CD11b Antibody[ICRF44]

Elab Fluor® Violet 540 Anti-Human CD11b Antibody[ICRF44]